Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
482 participants
OBSERVATIONAL
2017-11-14
2018-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
NCT01703364
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00536341
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
NCT00774345
Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer
NCT05035615
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
NCT01649791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flow Cytometry
Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Specimens and/or spent samples that are visibly clotted
* Specimens and/or spent samples collected in K2EDTA anticoagulant older than 24 hours from time of collection
* Specimens and/or spent samples collected in Heparin or ACD anticoagulant older than 48 hours from time of collection
* Samples with insufficient volume to complete the protocol tests
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beckman Coulter, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian Padurean, MD
Role: PRINCIPAL_INVESTIGATOR
NeoGenomics Laboratories, Inc.
Mike Keeney
Role: PRINCIPAL_INVESTIGATOR
London Health Sciences Center
Joanne Luider
Role: PRINCIPAL_INVESTIGATOR
Calgary Laboratory Services
Wolfgang Kern
Role: PRINCIPAL_INVESTIGATOR
Munich Leukemia Laboratory
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NeoGenomics Laboratories, Inc.
Fort Myers, Florida, United States
Calgary Laboratory Services
Calgary, Alberta, Canada
London Health Sciences Center
London, Ontario, Canada
Munich Leukemia Laboratory
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B88558
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.